Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Primary Myelofibrosis 13Myeloproliferative Disorders 9Leukemia, Myeloid, Acute 8Thrombocythemia, Essential 6Polycythemia Vera 6Myelodysplastic Syndromes 5Leukemia 5Recurrence 3Neoplasms 3Lymphoma, T-Cell 3Graft vs Host Disease 3Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, T-Cell, Cutaneous 2Lymphoma 2Leukemia, Prolymphocytic, T-Cell 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hematologic Neoplasms 2Uveal Melanoma 1Thalassemia 1Targeted Therapy 1Prostatic Neoplasms 1Preleukemia 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Neoplasms by Histologic Type 1Mycosis Fungoides 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1

Interventions

Interviews as Topic 8Specimen Handling 6Practice Guidelines as Topic 6Standard of Care 5Patient Navigation 3Educational Status 3Telemedicine 2Methods 2Early Intervention, Educational 2theanine 1ruxolitinib 1axatilimab 1X-Rays 1Triptorelin Pamoate 1Tacrolimus 1Surveys and Questionnaires 1Stem Cell Transplantation 1Spiritual Therapies 1Restraint, Physical 1Resistance Training 1Psychotherapy 1Psilocybin 1Phantoms, Imaging 1Parenteral Nutrition, Total 1Parenteral Nutrition 1Mycophenolic Acid 1Magnetic Resonance Spectroscopy 1Health Promotion 1Exercise Test 1Dietary Supplements 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematopoietic and Lymphatic System Neoplasm × ruxolitinib × 90 days × Clear all
NCT07025538 2026-04-20

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

City of Hope Medical Center

Phase 1 Recruiting
42 enrolled

Hematopoietic and Lymphatic System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡